Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).

Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (P_{noninferiority}  =  .0065), which was within the noninferiority margin of 1.25.

Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.

Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.

Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi:  10.1200/JCO.21.02962

Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).

Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (P_{noninferiority}  =  .0065), which was within the noninferiority margin of 1.25.

Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.

Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.

Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi:  10.1200/JCO.21.02962

Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).

Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (P_{noninferiority}  =  .0065), which was within the noninferiority margin of 1.25.

Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.

Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.

Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi:  10.1200/JCO.21.02962

Key clinical point: A Western-style diet (rich in red and processed meat) is more strongly associated with colorectal cancer (CRC) incidence for tumors containing higher amounts of polyketide synthase (pks)+ Escherichia coli.

Major finding: The association between the Western diet score and CRC incidence was stronger for tumors with higher pks+ E. coli levels (P_{heterogeneity}  =  .014). Individuals in the highest vs lowest tertile of diet score with pks+ E. coli-high, -low, and -negative tumors had adjusted hazard ratios of 3.45 (95% CI 1.53-7.78; P_trend  =  .001), 1.22 (95% CI 0.57-2.63), and 1.10 (95% CI 0.85-1.42), respectively.

Study details: This study analyzed the dietary information of 134,775 individuals enrolled in 2 U.S.-wide longitudinal prospective cohort studies using semiquantitative food frequency questionnaires.

Disclosures: This study was sponsored by the US National Institutes of Health, among others. Some authors declared previously serving as advisors or consultants for or receiving research grants from various sources.

Source: Arima K et al. Western-style diet, pks island-carrying Escherichia coli, and colorectal cancer: Analyses from two large prospective cohort studies. Gastroenterology. 2022 (Jun 24). Doi:  10.1053/j.gastro.2022.06.054

Key clinical point: A Western-style diet (rich in red and processed meat) is more strongly associated with colorectal cancer (CRC) incidence for tumors containing higher amounts of polyketide synthase (pks)+ Escherichia coli.

Major finding: The association between the Western diet score and CRC incidence was stronger for tumors with higher pks+ E. coli levels (P_{heterogeneity}  =  .014). Individuals in the highest vs lowest tertile of diet score with pks+ E. coli-high, -low, and -negative tumors had adjusted hazard ratios of 3.45 (95% CI 1.53-7.78; P_trend  =  .001), 1.22 (95% CI 0.57-2.63), and 1.10 (95% CI 0.85-1.42), respectively.

Study details: This study analyzed the dietary information of 134,775 individuals enrolled in 2 U.S.-wide longitudinal prospective cohort studies using semiquantitative food frequency questionnaires.

Disclosures: This study was sponsored by the US National Institutes of Health, among others. Some authors declared previously serving as advisors or consultants for or receiving research grants from various sources.

Source: Arima K et al. Western-style diet, pks island-carrying Escherichia coli, and colorectal cancer: Analyses from two large prospective cohort studies. Gastroenterology. 2022 (Jun 24). Doi:  10.1053/j.gastro.2022.06.054

Key clinical point: A Western-style diet (rich in red and processed meat) is more strongly associated with colorectal cancer (CRC) incidence for tumors containing higher amounts of polyketide synthase (pks)+ Escherichia coli.

Major finding: The association between the Western diet score and CRC incidence was stronger for tumors with higher pks+ E. coli levels (P_{heterogeneity}  =  .014). Individuals in the highest vs lowest tertile of diet score with pks+ E. coli-high, -low, and -negative tumors had adjusted hazard ratios of 3.45 (95% CI 1.53-7.78; P_trend  =  .001), 1.22 (95% CI 0.57-2.63), and 1.10 (95% CI 0.85-1.42), respectively.

Study details: This study analyzed the dietary information of 134,775 individuals enrolled in 2 U.S.-wide longitudinal prospective cohort studies using semiquantitative food frequency questionnaires.

Disclosures: This study was sponsored by the US National Institutes of Health, among others. Some authors declared previously serving as advisors or consultants for or receiving research grants from various sources.

Source: Arima K et al. Western-style diet, pks island-carrying Escherichia coli, and colorectal cancer: Analyses from two large prospective cohort studies. Gastroenterology. 2022 (Jun 24). Doi:  10.1053/j.gastro.2022.06.054

Key clinical point: Use of circulating tumor DNA (ctDNA)-guided approach for treating stage II colon cancer decreases the use of adjuvant chemotherapy without altering the risk for recurrence.

Major finding: After a median follow-up of 37 months, patients receiving ctDNA-guided vs standard management had a lower adjuvant chemotherapy rate (15% vs 28%; relative risk 1.82; 95% CI 1.25-2.65) and a similar 2-year recurrence-free survival rate (93.5% vs 92.4%; absolute difference, 1.1 percentage points; 95% CI −4.1 to 6.2 [noninferiority margin −8.5 percentage points]).

Study details: The data come from a multicenter phase 2 trial, DYNAMIC, involving 455 patients with resected stage II colon cancer who were assigned to ctDNA-guided (n = 302) or standard (n = 153) management.

Disclosures: This study was sponsored by the Australian National Health and Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Tie J et al for the DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261-2272 (Jun 16). Doi: 10.1056/NEJMoa2200075

Key clinical point: Use of circulating tumor DNA (ctDNA)-guided approach for treating stage II colon cancer decreases the use of adjuvant chemotherapy without altering the risk for recurrence.

Major finding: After a median follow-up of 37 months, patients receiving ctDNA-guided vs standard management had a lower adjuvant chemotherapy rate (15% vs 28%; relative risk 1.82; 95% CI 1.25-2.65) and a similar 2-year recurrence-free survival rate (93.5% vs 92.4%; absolute difference, 1.1 percentage points; 95% CI −4.1 to 6.2 [noninferiority margin −8.5 percentage points]).

Study details: The data come from a multicenter phase 2 trial, DYNAMIC, involving 455 patients with resected stage II colon cancer who were assigned to ctDNA-guided (n = 302) or standard (n = 153) management.

Disclosures: This study was sponsored by the Australian National Health and Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Tie J et al for the DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261-2272 (Jun 16). Doi: 10.1056/NEJMoa2200075

Key clinical point: Use of circulating tumor DNA (ctDNA)-guided approach for treating stage II colon cancer decreases the use of adjuvant chemotherapy without altering the risk for recurrence.

Major finding: After a median follow-up of 37 months, patients receiving ctDNA-guided vs standard management had a lower adjuvant chemotherapy rate (15% vs 28%; relative risk 1.82; 95% CI 1.25-2.65) and a similar 2-year recurrence-free survival rate (93.5% vs 92.4%; absolute difference, 1.1 percentage points; 95% CI −4.1 to 6.2 [noninferiority margin −8.5 percentage points]).

Study details: The data come from a multicenter phase 2 trial, DYNAMIC, involving 455 patients with resected stage II colon cancer who were assigned to ctDNA-guided (n = 302) or standard (n = 153) management.

Disclosures: This study was sponsored by the Australian National Health and Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Tie J et al for the DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261-2272 (Jun 16). Doi: 10.1056/NEJMoa2200075

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Attempting discontinuation of biologic disease-modifying antirheumatic drugs (bDMARD) or tofacitinib may be a feasible option in patients with rheumatoid arthritis (RA) and can be pursued after achieving stable control of disease activity.

Major finding: During a mean follow-up period of 2.1 years after discontinuing bDMARD or tofacitinib, disease flare occurred in 76.3% of patients (incidence rate 0.36 per person-year), with the median time to flare being 1.6 years (95% CI 0.9-2.6 years) and 89% of patients regaining remission or low disease activity within 1 month of restarting the previous treatment.

Study details: This was a prospective, observational study including 97 patients with RA in sustained remission or low disease activity for ≥ 48 weeks after a stable treatment with bDMARD or tofacitinib who desired drug discontinuation but received a stable methotrexate dose during follow-up.

Disclosures: This study was supported by the National Hospital Organization, Japan. S Mori reported receiving lecture fees from various sources.

Source: Mori S et al. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLoS One. 2022;17(6):e0270391 (Jun 23). Doi: 10.1371/journal.pone.0270391

Key clinical point: Attempting discontinuation of biologic disease-modifying antirheumatic drugs (bDMARD) or tofacitinib may be a feasible option in patients with rheumatoid arthritis (RA) and can be pursued after achieving stable control of disease activity.

Major finding: During a mean follow-up period of 2.1 years after discontinuing bDMARD or tofacitinib, disease flare occurred in 76.3% of patients (incidence rate 0.36 per person-year), with the median time to flare being 1.6 years (95% CI 0.9-2.6 years) and 89% of patients regaining remission or low disease activity within 1 month of restarting the previous treatment.

Study details: This was a prospective, observational study including 97 patients with RA in sustained remission or low disease activity for ≥ 48 weeks after a stable treatment with bDMARD or tofacitinib who desired drug discontinuation but received a stable methotrexate dose during follow-up.

Disclosures: This study was supported by the National Hospital Organization, Japan. S Mori reported receiving lecture fees from various sources.

Source: Mori S et al. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLoS One. 2022;17(6):e0270391 (Jun 23). Doi: 10.1371/journal.pone.0270391

Key clinical point: Attempting discontinuation of biologic disease-modifying antirheumatic drugs (bDMARD) or tofacitinib may be a feasible option in patients with rheumatoid arthritis (RA) and can be pursued after achieving stable control of disease activity.

Major finding: During a mean follow-up period of 2.1 years after discontinuing bDMARD or tofacitinib, disease flare occurred in 76.3% of patients (incidence rate 0.36 per person-year), with the median time to flare being 1.6 years (95% CI 0.9-2.6 years) and 89% of patients regaining remission or low disease activity within 1 month of restarting the previous treatment.

Study details: This was a prospective, observational study including 97 patients with RA in sustained remission or low disease activity for ≥ 48 weeks after a stable treatment with bDMARD or tofacitinib who desired drug discontinuation but received a stable methotrexate dose during follow-up.

Disclosures: This study was supported by the National Hospital Organization, Japan. S Mori reported receiving lecture fees from various sources.

Source: Mori S et al. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLoS One. 2022;17(6):e0270391 (Jun 23). Doi: 10.1371/journal.pone.0270391

Key clinical point: Abatacept stabilized pulmonary function and joint inflammation in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and had a favorable safety profile.

Major finding: Abatacept improved or stabilized lung disease in 72% of patients, with the median survival until progression or death being 72 months (95% CI 34-110 months). No significant decrease in the forced vital capacity or diffusing capacity of the lung for carbon monoxide and a significant improvement in 28-joint Disease Activity Score (P  =  .024) were observed. Overall, 10.5% of patients reported severe adverse events.

Study details: This was a prospective, observational cohort study including 57 patients with RA-ILD who received abatacept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs, immunosuppressants, antifibrotic agents, or corticosteroids.

Disclosures: This study received grants from Fundación Andaluza de Reumatología and Instituto de Investigación Biomédica de Málaga, Spain. The authors declared no conflicts of interest.

Source: Mena-Vázquez N et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease. Biomedicines. 2022;10(7):1480 (Jun 22). Doi: 10.3390/biomedicines10071480

Key clinical point: Abatacept stabilized pulmonary function and joint inflammation in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and had a favorable safety profile.

Major finding: Abatacept improved or stabilized lung disease in 72% of patients, with the median survival until progression or death being 72 months (95% CI 34-110 months). No significant decrease in the forced vital capacity or diffusing capacity of the lung for carbon monoxide and a significant improvement in 28-joint Disease Activity Score (P  =  .024) were observed. Overall, 10.5% of patients reported severe adverse events.

Study details: This was a prospective, observational cohort study including 57 patients with RA-ILD who received abatacept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs, immunosuppressants, antifibrotic agents, or corticosteroids.

Disclosures: This study received grants from Fundación Andaluza de Reumatología and Instituto de Investigación Biomédica de Málaga, Spain. The authors declared no conflicts of interest.

Source: Mena-Vázquez N et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease. Biomedicines. 2022;10(7):1480 (Jun 22). Doi: 10.3390/biomedicines10071480

Key clinical point: Abatacept stabilized pulmonary function and joint inflammation in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and had a favorable safety profile.

Major finding: Abatacept improved or stabilized lung disease in 72% of patients, with the median survival until progression or death being 72 months (95% CI 34-110 months). No significant decrease in the forced vital capacity or diffusing capacity of the lung for carbon monoxide and a significant improvement in 28-joint Disease Activity Score (P  =  .024) were observed. Overall, 10.5% of patients reported severe adverse events.

Study details: This was a prospective, observational cohort study including 57 patients with RA-ILD who received abatacept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs, immunosuppressants, antifibrotic agents, or corticosteroids.

Disclosures: This study received grants from Fundación Andaluza de Reumatología and Instituto de Investigación Biomédica de Málaga, Spain. The authors declared no conflicts of interest.

Source: Mena-Vázquez N et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease. Biomedicines. 2022;10(7):1480 (Jun 22). Doi: 10.3390/biomedicines10071480

Key clinical point: Hospitalized patients with rheumatoid arthritis (RA) with vs without prior bariatric surgery were less likely to have in-hospital deaths, major morbidities, unfavorable discharges, and prolonged length of stay (LOS).

Major finding: Patients with vs without prior bariatric surgery were at a reduced risk for any morbidity (adjusted odds ratio [aOR] 0.45; 95% CI 0.42-0.48), in-hospital mortality (aOR 0.41; 95% CI 0.27-0.61), unfavorable discharge (aOR 0.48; 95% CI 0.44-0.53), and prolonged LOS (aOR 0.43; 95% CI 0.39-0.46).

Study details: This population-based, retrospective study included 33,075 hospitalized patients with morbid obesity and RA, of which 6615 patients with prior bariatric surgery were propensity-score matched with 26,460 patients without prior bariatric surgery.

Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.

Source: Lin I-C and Liu H. Impact of bariatric surgery on outcomes of patients with rheumatoid arthritis: A propensity score–matched analysis of US nationwide inpatient sample, 2005–2018. Obes Surg. 2022 (Jun 29). Doi: 10.1007/s11695-022-06177-8

Key clinical point: Hospitalized patients with rheumatoid arthritis (RA) with vs without prior bariatric surgery were less likely to have in-hospital deaths, major morbidities, unfavorable discharges, and prolonged length of stay (LOS).

Major finding: Patients with vs without prior bariatric surgery were at a reduced risk for any morbidity (adjusted odds ratio [aOR] 0.45; 95% CI 0.42-0.48), in-hospital mortality (aOR 0.41; 95% CI 0.27-0.61), unfavorable discharge (aOR 0.48; 95% CI 0.44-0.53), and prolonged LOS (aOR 0.43; 95% CI 0.39-0.46).

Study details: This population-based, retrospective study included 33,075 hospitalized patients with morbid obesity and RA, of which 6615 patients with prior bariatric surgery were propensity-score matched with 26,460 patients without prior bariatric surgery.

Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.

Source: Lin I-C and Liu H. Impact of bariatric surgery on outcomes of patients with rheumatoid arthritis: A propensity score–matched analysis of US nationwide inpatient sample, 2005–2018. Obes Surg. 2022 (Jun 29). Doi: 10.1007/s11695-022-06177-8

Key clinical point: Hospitalized patients with rheumatoid arthritis (RA) with vs without prior bariatric surgery were less likely to have in-hospital deaths, major morbidities, unfavorable discharges, and prolonged length of stay (LOS).

Major finding: Patients with vs without prior bariatric surgery were at a reduced risk for any morbidity (adjusted odds ratio [aOR] 0.45; 95% CI 0.42-0.48), in-hospital mortality (aOR 0.41; 95% CI 0.27-0.61), unfavorable discharge (aOR 0.48; 95% CI 0.44-0.53), and prolonged LOS (aOR 0.43; 95% CI 0.39-0.46).

Study details: This population-based, retrospective study included 33,075 hospitalized patients with morbid obesity and RA, of which 6615 patients with prior bariatric surgery were propensity-score matched with 26,460 patients without prior bariatric surgery.

Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.

Source: Lin I-C and Liu H. Impact of bariatric surgery on outcomes of patients with rheumatoid arthritis: A propensity score–matched analysis of US nationwide inpatient sample, 2005–2018. Obes Surg. 2022 (Jun 29). Doi: 10.1007/s11695-022-06177-8

Key clinical point: Sarcopenia and poor balance were associated with a higher risk for vertebral spinal osteoporotic fracture (VOPF), disease activity, and joint structure damage in women with rheumatoid arthritis (RA).

Major finding: Women with vs without RA had a significantly higher incidence of sarcopenia (60.0% vs 11.1%; P < .0001), poor balance (44.1% vs 7.9%; P < .0001), and VOPF (21% vs 3.2%; P < .0001). Among women with RA, those with vs without VOPF had a significantly higher incidence of sarcopenia (75.6% vs 55.8%; P < .0001) and poor balance (68.3% vs 37.7%; P < .0001) and those with vs without sarcopenia and poor balance had a higher disease activity, more serious joint damage, and worse joint function (all P < .05).

Study details: This study included 195 women with RA and 126 age- and sex-matched healthy individuals.

Disclosures: This study did not declare any source of funding. The authors declared no competing interests.

Source: Zhang M et al. Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis. Sci Rep. 2022;12:9477 (Jun 8). Doi: 10.1038/s41598-022-13339-2

Key clinical point: Sarcopenia and poor balance were associated with a higher risk for vertebral spinal osteoporotic fracture (VOPF), disease activity, and joint structure damage in women with rheumatoid arthritis (RA).

Major finding: Women with vs without RA had a significantly higher incidence of sarcopenia (60.0% vs 11.1%; P < .0001), poor balance (44.1% vs 7.9%; P < .0001), and VOPF (21% vs 3.2%; P < .0001). Among women with RA, those with vs without VOPF had a significantly higher incidence of sarcopenia (75.6% vs 55.8%; P < .0001) and poor balance (68.3% vs 37.7%; P < .0001) and those with vs without sarcopenia and poor balance had a higher disease activity, more serious joint damage, and worse joint function (all P < .05).

Study details: This study included 195 women with RA and 126 age- and sex-matched healthy individuals.

Disclosures: This study did not declare any source of funding. The authors declared no competing interests.

Source: Zhang M et al. Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis. Sci Rep. 2022;12:9477 (Jun 8). Doi: 10.1038/s41598-022-13339-2

Key clinical point: Sarcopenia and poor balance were associated with a higher risk for vertebral spinal osteoporotic fracture (VOPF), disease activity, and joint structure damage in women with rheumatoid arthritis (RA).

Major finding: Women with vs without RA had a significantly higher incidence of sarcopenia (60.0% vs 11.1%; P < .0001), poor balance (44.1% vs 7.9%; P < .0001), and VOPF (21% vs 3.2%; P < .0001). Among women with RA, those with vs without VOPF had a significantly higher incidence of sarcopenia (75.6% vs 55.8%; P < .0001) and poor balance (68.3% vs 37.7%; P < .0001) and those with vs without sarcopenia and poor balance had a higher disease activity, more serious joint damage, and worse joint function (all P < .05).

Study details: This study included 195 women with RA and 126 age- and sex-matched healthy individuals.

Disclosures: This study did not declare any source of funding. The authors declared no competing interests.

Source: Zhang M et al. Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis. Sci Rep. 2022;12:9477 (Jun 8). Doi: 10.1038/s41598-022-13339-2

Key clinical point: Upadacitinib vs abatacept treatment resulted in rapid and greater improvements in patient-reported physical function, pain, and overall health in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to biologic disease modifying antirheumatic drugs (bDMARDs-IR).

Major finding: At 12 weeks, a higher proportion of patients receiving upadacitinib vs abatacept reported clinically meaningful improvements in the Health Assessment Questionnaire Disability Index (HAQ-DI; 74% vs 64%; P < .05), with significant improvements in patient-assessed disease activity (least-squares mean change [LSMC] −33.9 vs −28.4), pain (LSMC −35.3 vs −30.0), HAQ-DI (LSMC −0.65 vs −0.48), and EQ-5D-5L index (LSMC 0.26 vs 0.21; all P < .05) scores.

Study details: Findings are from a post hoc analysis of the SELECT-CHOICE phase 3 trial including 612 patients with moderate-to-severe RA and bDMARDs-IR patients who were randomly assigned to receive upadacitinib or abatacept with concomitant conventional synthetic disease modifying antirheumatic drugs.

Disclosures: This study was funded by AbbVie Inc. Six authors declared being current or former employees or stockholders of AbbVie or a company receiving consulting fees from AbbVie. The other authors reported ties with AbbVie and various sources.

Source: Bergman M et al. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther. 2022;24:15 (Jun 24). Doi: 10.1186/s13075-022-02813-x

Key clinical point: Upadacitinib vs abatacept treatment resulted in rapid and greater improvements in patient-reported physical function, pain, and overall health in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to biologic disease modifying antirheumatic drugs (bDMARDs-IR).

Major finding: At 12 weeks, a higher proportion of patients receiving upadacitinib vs abatacept reported clinically meaningful improvements in the Health Assessment Questionnaire Disability Index (HAQ-DI; 74% vs 64%; P < .05), with significant improvements in patient-assessed disease activity (least-squares mean change [LSMC] −33.9 vs −28.4), pain (LSMC −35.3 vs −30.0), HAQ-DI (LSMC −0.65 vs −0.48), and EQ-5D-5L index (LSMC 0.26 vs 0.21; all P < .05) scores.

Study details: Findings are from a post hoc analysis of the SELECT-CHOICE phase 3 trial including 612 patients with moderate-to-severe RA and bDMARDs-IR patients who were randomly assigned to receive upadacitinib or abatacept with concomitant conventional synthetic disease modifying antirheumatic drugs.

Disclosures: This study was funded by AbbVie Inc. Six authors declared being current or former employees or stockholders of AbbVie or a company receiving consulting fees from AbbVie. The other authors reported ties with AbbVie and various sources.

Source: Bergman M et al. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther. 2022;24:15 (Jun 24). Doi: 10.1186/s13075-022-02813-x

Key clinical point: Upadacitinib vs abatacept treatment resulted in rapid and greater improvements in patient-reported physical function, pain, and overall health in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to biologic disease modifying antirheumatic drugs (bDMARDs-IR).

Major finding: At 12 weeks, a higher proportion of patients receiving upadacitinib vs abatacept reported clinically meaningful improvements in the Health Assessment Questionnaire Disability Index (HAQ-DI; 74% vs 64%; P < .05), with significant improvements in patient-assessed disease activity (least-squares mean change [LSMC] −33.9 vs −28.4), pain (LSMC −35.3 vs −30.0), HAQ-DI (LSMC −0.65 vs −0.48), and EQ-5D-5L index (LSMC 0.26 vs 0.21; all P < .05) scores.

Study details: Findings are from a post hoc analysis of the SELECT-CHOICE phase 3 trial including 612 patients with moderate-to-severe RA and bDMARDs-IR patients who were randomly assigned to receive upadacitinib or abatacept with concomitant conventional synthetic disease modifying antirheumatic drugs.

Disclosures: This study was funded by AbbVie Inc. Six authors declared being current or former employees or stockholders of AbbVie or a company receiving consulting fees from AbbVie. The other authors reported ties with AbbVie and various sources.

Source: Bergman M et al. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther. 2022;24:15 (Jun 24). Doi: 10.1186/s13075-022-02813-x

Key clinical point: Ozoralizumab at a dose of 30 or 80 mg significantly improved clinical outcomes compared to placebo and was well tolerated with no new safety signals in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate therapy.

Major finding: A significantly higher proportion of patients receiving 30/80 mg ozoralizumab vs placebo achieved ≥ 20% improvement in American College of Rheumatology criteria (79.6%/75.3% vs 37.3%; P < .001) at 16 weeks and had structural damage nonprogression (73.0%/73.4% vs 56.0%; P < .01) at 24 weeks. No new adverse events were reported.

Study details: The data come from the phase 2/3 OHZORA trial including 381 patients with active RA and an inadequate response to methotrexate who were randomly assigned to receive ozoralizumab (30 or 80 mg) or placebo in combination with methotrexate for 24 weeks.

Disclosures: This trial was sponsored by Taisho Pharmaceutical Co., Ltd. Three authors reported being employees of Taisho Pharmaceutical. Several authors reported receiving grants, consulting fees, or speaking fees from various sources.

Source: Takeuchi T et al. Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial). Arthritis Rheumatol. 2022 Jun 21. doi: 10.1002/art.42273.

Key clinical point: Ozoralizumab at a dose of 30 or 80 mg significantly improved clinical outcomes compared to placebo and was well tolerated with no new safety signals in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate therapy.

Major finding: A significantly higher proportion of patients receiving 30/80 mg ozoralizumab vs placebo achieved ≥ 20% improvement in American College of Rheumatology criteria (79.6%/75.3% vs 37.3%; P < .001) at 16 weeks and had structural damage nonprogression (73.0%/73.4% vs 56.0%; P < .01) at 24 weeks. No new adverse events were reported.

Study details: The data come from the phase 2/3 OHZORA trial including 381 patients with active RA and an inadequate response to methotrexate who were randomly assigned to receive ozoralizumab (30 or 80 mg) or placebo in combination with methotrexate for 24 weeks.

Disclosures: This trial was sponsored by Taisho Pharmaceutical Co., Ltd. Three authors reported being employees of Taisho Pharmaceutical. Several authors reported receiving grants, consulting fees, or speaking fees from various sources.

Source: Takeuchi T et al. Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial). Arthritis Rheumatol. 2022 Jun 21. doi: 10.1002/art.42273.

Key clinical point: Ozoralizumab at a dose of 30 or 80 mg significantly improved clinical outcomes compared to placebo and was well tolerated with no new safety signals in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate therapy.

Major finding: A significantly higher proportion of patients receiving 30/80 mg ozoralizumab vs placebo achieved ≥ 20% improvement in American College of Rheumatology criteria (79.6%/75.3% vs 37.3%; P < .001) at 16 weeks and had structural damage nonprogression (73.0%/73.4% vs 56.0%; P < .01) at 24 weeks. No new adverse events were reported.

Study details: The data come from the phase 2/3 OHZORA trial including 381 patients with active RA and an inadequate response to methotrexate who were randomly assigned to receive ozoralizumab (30 or 80 mg) or placebo in combination with methotrexate for 24 weeks.

Disclosures: This trial was sponsored by Taisho Pharmaceutical Co., Ltd. Three authors reported being employees of Taisho Pharmaceutical. Several authors reported receiving grants, consulting fees, or speaking fees from various sources.

Source: Takeuchi T et al. Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial). Arthritis Rheumatol. 2022 Jun 21. doi: 10.1002/art.42273.